Technology

Start managing the transformation now to secure every benefit.

From CRM saturation to commercial orchestration.

Eli Lilly and NVIDIA unveil a groundbreaking AI supercomputer, revolutionizing drug discovery and accelerating patient care through advanced technology.

AI transforms pharmaceutical operations by automating workflows, ensuring transparency, and enhancing compliance, driving efficiency and innovation in healthcare.

A blueprint for how companies can move from isolated pilots toward effective AI implementation.

The importance for pharma in recognizing integrated data sources as necessary infrastructure—not just a competitive edge.

Nabla Bio and Takeda enhance their partnership to revolutionize AI-driven protein therapeutics, aiming for groundbreaking advancements in drug development.

Developing a medical AI model is defining the parameters of the problem that needs to be solved.

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

Merck’s executive director, operations lead, global medical affairs and outcomes research discusses how data is helping to identify scientific leaders.

The key steps for pharma in pivoting from proof-of-concept experimenting to enterprise-scale value.

With healthcare at a key crossroads of policy, technology, and science, Sanofi CEO Paul Hudson shares the Big Pharma’s formula for navigating the new age of innovation, where running from risk is not an option.

As drugmakers navigate an increasingly complex terrain of scientific and digital influence, the ability to accurately identify and understand both key and digital opinion leaders is vital for effective engagement.

A Harvard Business School Healthcare Alumni Q&A with Professor Eric Mazur of Harvard University.

Powering learnings of the dark genome to tackle disease at its source.

Pushing for access wins in quickly evolving market and digital health landscapes.

Ex-Wall Street trader is helping reshape how patients receive biologics.

Pioneer of cell-reset technology steers science-to-startup transformation.

The AeroRx Therapeutics CEO discusses new treatments and how the industry at large is reacting to them.

The Google Cloud director discusses AI implementation and workflow.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

Bridging the last mile to clinical actionability.

With AI expected to play a significant role in drug approvals, how can companies build data sets that are ready for AI?

Gene Mack, CEO, Gain Therapeutics, explains how the company’s Magellan AI platform analyzes novel protein binding sites to identify and design drug candidates beyond what’s currently available in the public domain.

By using real-world data (RWD) and the insights derived from it, real-world evidence (RWE) earlier in research and development, drugmakers can make more informed decisions and reduce the financial risks that drive up drug prices.